PsyNamic: A living systematic review of psychedelic therapy in psychiatric disorders
Abstract
The resurgence of interest in the therapeutic potential of psychedelic substances for psychiatric disorders has heralded a new era of clinical research. Substances such as LSD, psilocybin, mescaline, DMT, 5-MeO-DMT, MDMA, ketamine, ibogaine, and salvinorin A are being investigated for their efficacy in treating conditions like eating disorders, depression, and anxiety. However, the rapid accumulation of clinical trial data presents a challenge for manual synthesis and the continuous updating of evidence. This study aims to address this gap by establishing a living systematic review that dynamically incorporates new research findings on the use of psychedelic substances in psychiatric treatment. Utilizing natural language processing (NLP) techniques, including large language models, we plan to automate the classification of studies and extraction of relevant data. Our approach will enable the real-time synthesis of evidence, ensuring that the most current data is readily accessible. The outcomes of this research will be freely available in an online data warehouse, providing a comprehensive and up-to-date resource for both clinicians planning future trials and interested laypersons seeking evidence-based information on psychedelic therapy. This endeavor promises to enhance the efficiency of evidence synthesis in the burgeoning field of psychedelic research and offer insights for the evidence-based application of psychedelic therapy in psychiatric care for lay people.
Topics & conditions
Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.
Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.